A fast track designation has been granted by the FDA to the novel BTK degrader, NX-5948, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
Patients insured by Medicare can now receive coverage for lymphedema compression garments as a result of the Lymphedema Treatment Act, but it is essential that oncology nurses communicate this with their patients.
Treatment with asciminib for newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase induced statistically significant and clinically meaningful major molecular response benefits compared with standard-of-care TKIs.
Treatment with pegylated liposomal doxorubicin and cyclophosphamide in the neoadjuvant setting, followed by a taxane, in addition to trastuzumab and pertuzumab, resulted in antitumor activity in patients with HER2-positive breast cancer.
The rate of initiating immunotherapy towards the end of life in patients with advanced cancers, including renal cell carcinoma, melanoma, and non-small cell lung cancer, is increasing over time.
Speaking with patients with cancer about financial toxicity, including available resources to help them pay for treatment and other necessities, can become a collaborative effort within an institution.
RC88, a mesothelin-targeting antibody-drug conjugate, was granted a fast track designation from the FDA for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
A breakthrough therapy designation has been granted by the FDA to TAR-200 for the treatment of Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer who are not eligible for or opted not to receive radical cystectomy.
A new drug application for SH-105 has been accepted by the FDA to potentially treat patients with breast and ovarian cancer.
Pembrolizumab plus chemoradiotherapy has been approved by the FDA for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer.
SLS009 has been granted fast track status from the FDA to be considered as a potential therapeutic option for relapsed or refractory acute myeloid leukemia.
A disease-free survival benefit continued with adjuvant pembrolizumab when compared with placebo in patients with resected early-stage NSCLC.
Oncology nurses can bring creative art to their pediatric patients with cancer, thereby potentially reducing their anxiety levels, research showed.
Three patients with resectable hepatocellular carcinoma experienced significant tumor necrosis greater than 70% after neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc, in addition to adjuvant cemiplimab.
Findings from the phase 3b LUMINANCE study aligned with safety and efficacy outcomes from the phase 3 CASPIAN trial, both of which focused on the administration of 5 or more cycles of induction platinum/etoposide alongside durvalumab for the treatment of patients with extensive-stage small cell lung cancer.
A supplemental biologics license application has been granted priority review by the FDA, which seeks a full approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer that progressed on or following frontline therapy.
A survival advantage via treatment with lenvatinib plus pembrolizumab was not seen when compared with docetaxel for advanced-stage non–small cell lung cancer whose disease progressed after previous exposure to a PD-L1 inhibitor and platinum-based chemotherapy.
Next-generation sequencing may better predict dMMR in patients with colorectal or endometrial cancer, highlighting the importance of the testing.
After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.
Adding a limited course of tremelimumab to frontline durvalumab and chemotherapy may provide patients with previously untreated metastatic non-small cell lung cancer a sustained overall survival benefit compared with chemotherapy alone.
Reducing the dose of talquetamab, a GPRC5D/CD3 bispecific antibody, may improve side effect rates while maintain high response rates in patients with relapsed or refractory multiple myeloma.
The Food and Drug Administration approved an on-body delivery system for pegfilgrastim-cbqv, a biosimilar of pegfilgrastim.
Oncology nurses may play a role in the utilization of artificial intelligence in the clinical setting.
When compared with palbociclib and fulvestrant, adding inavolisib to the regimen improved progression-free survival in some patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer.
The survival benefit derived from T-DM1—particularly invasive disease-free survival and overall survival—persisted throughout 8 years of follow-up in HER2-positive early breast cancer with residual invasive disease.
Blinatumomab tended to be safe and effective in the treatment of children or young adults with B-cell acute lymphoblastic leukemia, potentially offering a treatment regimen less toxic than chemotherapy.
Oncology nurses can illuminate the potential of avasopasem to enhance pancreatic cancer outcomes and champion ongoing research.
The median overall survival among those treated with tisagenlecleucel was not reached, and the 36-month overall survival rate was 82%.
The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
